-
1
-
-
63449139456
-
Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding
-
Aller SG, Yu J, Ward A, et al. (2009). Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323: 1718-22.
-
(2009)
Science
, vol.323
, pp. 1718-1722
-
-
Aller, S.G.1
Yu, J.2
Ward, A.3
-
2
-
-
0028948839
-
A theoretical basis for a biopharmaceutic drug classification: The correlation in vitro drug product dissolution and in vivo bioavailability
-
Amidon GL, Lennernäs H, Shah VP, Crison Jr. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12: 413-20.
-
(1995)
Pharm Res
, vol.12
, pp. 413-420
-
-
Amidon, G.L.1
Lennernäs, H.2
Shah, V.P.3
Crison, J.R.4
-
3
-
-
84882696152
-
P-glycoprotein inhibition for optimal drug delivery
-
Amin ML. (2013). P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights 7: 27-34.
-
(2013)
Drug Target Insights
, vol.7
, pp. 27-34
-
-
Amin, M.L.1
-
5
-
-
2442719906
-
Unmasking the dynamic interplay between efflux transporters and metabolic enzymes
-
DOI 10.1016/j.ijpharm.2002.12.002, PII S0378517304001255
-
Benet LZ, Cummins CL, Wu CY. (2004). Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm 277: 3-9. (Pubitemid 38670415)
-
(2004)
International Journal of Pharmaceutics
, vol.277
, Issue.1-2
, pp. 3-9
-
-
Benet, L.Z.1
Cummins, C.L.2
Wu, C.Y.3
-
6
-
-
30344487254
-
Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs
-
DOI 10.1016/j.tips.2005.11.009, PII S016561470500310X
-
Breedveld P, Beijnen JH, Schellens JH. (2006). Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci 27: 17-24. (Pubitemid 43063120)
-
(2006)
Trends in Pharmacological Sciences
, vol.27
, Issue.1
, pp. 17-24
-
-
Breedveld, P.1
Beijnen, J.H.2
Schellens, J.H.M.3
-
7
-
-
40749103835
-
SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase - Dependent cancers
-
DOI 10.1158/1078-0432.CCR-07-1667
-
Chandarlapaty S, Sawai A, Ye Q, et al. (2008). SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res 14: 240-8. (Pubitemid 351378001)
-
(2008)
Clinical Cancer Research
, vol.14
, Issue.1
, pp. 240-248
-
-
Chandarlapaty, S.1
Sawai, A.2
Ye, Q.3
Scott, A.4
Silinski, M.5
Huang, K.6
Fadden, P.7
Partdrige, J.8
Hall, S.9
Steed, P.10
Norton, L.11
Rosen, N.12
Solit, D.B.13
-
8
-
-
0037371414
-
Metabolism of flavonoids via enteric recycling: Role of intestinal disposition
-
DOI 10.1124/jpet.102.046409
-
Chen J, Lin H, Hu M. (2003). Metabolism of flavonoids via enteric recycling: role of intestinal disposition. J Pharmacol Exp Ther 304: 1228-35. (Pubitemid 36254436)
-
(2003)
Journal of Pharmacology and Experimental Therapeutics
, vol.304
, Issue.3
, pp. 1228-1235
-
-
Chen, J.1
Lin, H.2
Hu, M.3
-
9
-
-
84859269331
-
Computational models for predicting substrates or inhibitors of P-glycoprotein
-
Chen L, Li Y, Yu H, et al. (2012). Computational models for predicting substrates or inhibitors of P-glycoprotein. Drug Discov Today 17: 343-51.
-
(2012)
Drug Discov Today
, vol.17
, pp. 343-351
-
-
Chen, L.1
Li, Y.2
Yu, H.3
-
10
-
-
0033980182
-
P-glycoprotein: A defense mechanism limiting oral bioavailability and CNS accumulation of drugs
-
Fromm MF. (2000). P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 38: 69-74. (Pubitemid 30077981)
-
(2000)
International Journal of Clinical Pharmacology and Therapeutics
, vol.38
, Issue.2
, pp. 69-74
-
-
Fromm, M.F.1
-
11
-
-
0242552872
-
Importance of P-glycoprotein for drug disposition in humans
-
Fromm MF. (2003). Importance of P-glycoprotein for drug disposition in humans. Eur J Clin Invest 33 Suppl 2: 6-9.
-
(2003)
Eur J Clin Invest
, vol.33
, Issue.SUPPL. 2
, pp. 6-9
-
-
Fromm, M.F.1
-
12
-
-
78649661850
-
Importance of P-glycoprotein for drug-drug interactions
-
Glaeser H. (2011). Importance of P-glycoprotein for drug-drug interactions. Handb Exp Pharmacol 201: 285-97.
-
(2011)
Handb Exp Pharmacol
, vol.201
, pp. 285-297
-
-
Glaeser, H.1
-
13
-
-
0036889665
-
Endogenous drug transporters in in vitro and in vivo models for the prediction of drug disposition in man
-
DOI 10.1016/S0006-2952(02)01355-2, PII S0006295202013552
-
Goh LB, Spears KJ, Yao D, et al. (2002). Endogenous drug transporters in in vitro and in vivo models for the prediction of drug disposition in man. Biochem Pharmacol 64: 1569-78. (Pubitemid 35333418)
-
(2002)
Biochemical Pharmacology
, vol.64
, Issue.11
, pp. 1569-1578
-
-
Goh, L.-B.1
Spears, K.J.2
Yao, D.3
Ayrton, A.4
Morgan, P.5
Roland Wolf, C.6
Friedberg, T.7
-
15
-
-
67650741952
-
Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents
-
Huang KH, Veal JM, Fadden RP, et al. (2009). Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. J Med Chem 52: 4288-305.
-
(2009)
J Med Chem
, vol.52
, pp. 4288-4305
-
-
Huang, K.H.1
Veal, J.M.2
Fadden, R.P.3
-
16
-
-
0027524642
-
In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative
-
Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. (1993). In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53: 4595-602. (Pubitemid 23304385)
-
(1993)
Cancer Research
, vol.53
, Issue.18
, pp. 4595-4602
-
-
Hyafil, F.1
Vergely, C.2
Du Vignaud, P.3
Grand-Perret, T.4
-
17
-
-
0032949615
-
MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening
-
DOI 10.1021/js9803205
-
Irvine JD, Takahashi L, Lockhart K, et al. (1999). MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening. J Pharm Sci 88: 28-33. (Pubitemid 29037364)
-
(1999)
Journal of Pharmaceutical Sciences
, vol.88
, Issue.1
, pp. 28-33
-
-
Irvine, J.D.1
Takahashi, L.2
Lockhart, K.3
Cheong, J.4
Tolan, J.W.5
Selick, H.E.6
Grove, J.R.7
-
18
-
-
33645399844
-
In situ single-pass perfused rat intestinal model for absorption and metabolism
-
Yan Z, Caldwell GW, eds., Totowa: Humana Press Inc
-
Jeong EJ, Liu Y, Lin H, Hu M. (2004) In situ single-pass perfused rat intestinal model for absorption and metabolism. In: Yan Z, Caldwell GW, eds. Methods in pharmacology and toxicology optimization in drug discovery: in vitro methods. Totowa: Humana Press Inc, 65-76.
-
(2004)
Methods in Pharmacology and Toxicology Optimization in Drug Discovery: In Vitro Methods
, pp. 65-76
-
-
Jeong, E.J.1
Liu, Y.2
Lin, H.3
Hu, M.4
-
19
-
-
0023940704
-
Determination of intrinsic membrane transport parameters from perfused intestine experiments: A boundary layer approach to estimating the aqueous and unbiased membrane permeabilities
-
Johnson DA, Amidon GL. (1988). Determination of intrinsic membrane transport parameters from perfused intestine experiments: a boundary layer approach to estimating the aqueous and unbiased membrane permeabilities. J Theor Biol 131: 93-106.
-
(1988)
J Theor Biol
, vol.131
, pp. 93-106
-
-
Johnson, D.A.1
Amidon, G.L.2
-
20
-
-
4143108324
-
Substrate depletion approach for determining in vitro metabolic clearance: Time dependencies in hepatocyte and microsomal incubations
-
DOI 10.1124/dmd.104.000125
-
Jones HM, Houston JB. (2004). Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations. Drug Metab Dispos 32: 973-82. (Pubitemid 39096058)
-
(2004)
Drug Metabolism and Disposition
, vol.32
, Issue.9
, pp. 973-982
-
-
Jones, H.M.1
Houston, J.B.2
-
21
-
-
84885089993
-
Structure-activity relationships and in silico models of P-glycoprotein (ABCB1) inhibitors
-
Liu H, Ma Z, Wu B. (2013). Structure-activity relationships and in silico models of P-glycoprotein (ABCB1) inhibitors. Xenobiotica 43: 1018-26.
-
(2013)
Xenobiotica
, vol.43
, pp. 1018-1026
-
-
Liu, H.1
Ma, Z.2
Wu, B.3
-
22
-
-
84898712261
-
Metabolite elucidation of the Hsp90 inhibitor SNX-2112 using ultraperformance liquid chromatography/ quadrupole time-of-flight mass spectrometry (UPLC-QTOF/ MS)
-
(in press), [Epub ahead of print]. doi: 10.3109/00498254.2013.853849
-
Liu W, Liu H, Sun H, et al. (in press). Metabolite elucidation of the Hsp90 inhibitor SNX-2112 using ultraperformance liquid chromatography/ quadrupole time-of-flight mass spectrometry (UPLC-QTOF/ MS). Xenobiotica. [Epub ahead of print]. doi: 10.3109/ 00498254.2013.853849.
-
Xenobiotica
-
-
Liu, W.1
Liu, H.2
Sun, H.3
-
23
-
-
27644444057
-
Unbiased membrane permeability parameters for gabapentin using boundary layer approach
-
DOI 10.1208/aapsj070121, 21
-
Madan J, Chawla G, Arora V, et al. (2005). Unbiased membrane permeability parameters for gabapentin using boundary layer approach. AAPS J 7:E224-30. (Pubitemid 41554286)
-
(2005)
AAPS Journal
, vol.7
, Issue.1
-
-
Madan, J.1
Chawla, G.2
Arora, V.3
Malik, R.4
Bansal, A.K.5
-
25
-
-
84874267225
-
The therapeutic target Hsp90 and cancer hallmarks
-
Miyata Y, Nakamoto H, Neckers L. (2013). The therapeutic target Hsp90 and cancer hallmarks. Curr Pharm Des 19: 347-65.
-
(2013)
Curr Pharm des
, vol.19
, pp. 347-365
-
-
Miyata, Y.1
Nakamoto, H.2
Neckers, L.3
-
26
-
-
59649086503
-
SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK
-
Okawa Y, Hideshima T, Steed P, et al. (2009). SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood 113: 846-55.
-
(2009)
Blood
, vol.113
, pp. 846-855
-
-
Okawa, Y.1
Hideshima, T.2
Steed, P.3
-
27
-
-
73949109329
-
Expression and function of p-glycoprotein in normal tissues: Effect on pharmacokinetics
-
Staud F, Ceckova M, Micuda S, Pavek P. (2010). Expression and function of p-glycoprotein in normal tissues: effect on pharmacokinetics. Methods Mol Biol 596: 199-222.
-
(2010)
Methods Mol Biol
, vol.596
, pp. 199-222
-
-
Staud, F.1
Ceckova, M.2
Micuda, S.3
Pavek, P.4
-
28
-
-
79851478871
-
Predicting drugdrug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein
-
Tachibana T, Kato M, Takano J, Sugiyama Y. (2010). Predicting drugdrug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein. Curr Drug Metab 11: 762-77.
-
(2010)
Curr Drug Metab
, vol.11
, pp. 762-777
-
-
Tachibana, T.1
Kato, M.2
Takano, J.3
Sugiyama, Y.4
-
29
-
-
0036293772
-
Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa?
-
DOI 10.1023/A:1016140429238
-
Tang F, Horie K, Borchardt RT. (2002). Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res 19: 765-72. (Pubitemid 34686734)
-
(2002)
Pharmaceutical Research
, vol.19
, Issue.6
, pp. 765-772
-
-
Tang, F.1
Horie, K.2
Borchardt, R.T.3
-
30
-
-
0033975157
-
Role of P-glycoprotein in drug disposition
-
DOI 10.1097/00007691-200002000-00029
-
Tanigawara Y. (2000). Role of P-glycoprotein in drug disposition. Ther Drug Monit 22: 137-40. (Pubitemid 30083115)
-
(2000)
Therapeutic Drug Monitoring
, vol.22
, Issue.1
, pp. 137-140
-
-
Tanigawara, Y.1
-
31
-
-
16544377891
-
Profile of P-glycoprotien distribution in the rat and its possible influence on the salbutamol intestinal absorption process
-
DOI 10.1002/jps.20071
-
Valenzuela B, Nácher A, Ruiz-Carretero P, et al. (2004). Profile of P-glycoprotein distribution in the rat and its possible influence on the salbutamol intestinal absorption process. J Pharm Sci 93: 1641-8. (Pubitemid 38725034)
-
(2004)
Journal of Pharmaceutical Sciences
, vol.93
, Issue.6
, pp. 1641-1648
-
-
Valenzuela, B.1
Nacher, A.2
Ruiz-Carretero, P.3
Martin-Villodre, A.4
Lopez-Carballo, G.5
Barettino, D.6
-
32
-
-
14644419054
-
Functional role of P-glycoprotein in limiting intestinal absorption of drugs: Contribution of passive permeability to P-glycoprotein mediated efflux transport
-
DOI 10.1021/mp0499196
-
Varma MV, Sateesh K, Panchagnula R. (2005). Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport. Mol Pharm 2: 12-21. (Pubitemid 40314725)
-
(2005)
Molecular Pharmaceutics
, vol.2
, Issue.1
, pp. 12-21
-
-
Varma, M.V.S.1
Sateesh, K.2
Panchagnula, R.3
-
33
-
-
81855206518
-
Drug-permeability and transporter assays in Caco-2 and MDCK cell lines
-
Volpe DA. (2011). Drug-permeability and transporter assays in Caco-2 and MDCK cell lines. Future Med Chem 3: 2063-77.
-
(2011)
Future Med Chem
, vol.3
, pp. 2063-2077
-
-
Volpe, D.A.1
-
34
-
-
25844519550
-
HSP90 and the chaperoning of cancer
-
DOI 10.1038/nrc1716
-
Whitesell L, Lindquist SL. (2005). HSP90 and the chaperoning of cancer. Nat Rev Cancer 5: 761-72. (Pubitemid 41400776)
-
(2005)
Nature Reviews Cancer
, vol.5
, Issue.10
, pp. 761-772
-
-
Whitesell, L.1
Lindquist, S.L.2
-
35
-
-
71949113516
-
Disposition of naringenin via glucuronidation pathway is affected by compensating efflux transporters of hydrophilic glucuronides
-
Xu H, Kulkarni KH, Singh R, et al. (2009). Disposition of naringenin via glucuronidation pathway is affected by compensating efflux transporters of hydrophilic glucuronides. Mol Pharm 6: 1703-15.
-
(2009)
Mol Pharm
, vol.6
, pp. 1703-1715
-
-
Xu, H.1
Kulkarni, K.H.2
Singh, R.3
-
36
-
-
80053155942
-
Enhancement of oral bioavailability of 20(S)-ginsenoside Rh2 through improved understanding of its absorption and efflux mechanisms
-
Yang Z, Gao S, Wang J, et al. (2011). Enhancement of oral bioavailability of 20(S)-ginsenoside Rh2 through improved understanding of its absorption and efflux mechanisms. Drug Metab Dispos 39: 1866-72.
-
(2011)
Drug Metab Dispos
, vol.39
, pp. 1866-1872
-
-
Yang, Z.1
Gao, S.2
Wang, J.3
-
37
-
-
80053221096
-
Poor oral bioavailability of a promising anticancer agent andrographolide is due to extensive metabolism and efflux by P-glycoprotein
-
Ye L, Wang T, Tang L, et al. (2011). Poor oral bioavailability of a promising anticancer agent andrographolide is due to extensive metabolism and efflux by P-glycoprotein. J Pharm Sci 100: 5007-17.
-
(2011)
J Pharm Sci
, vol.100
, pp. 5007-5017
-
-
Ye, L.1
Wang, T.2
Tang, L.3
|